Heart failure and transplantation with Dr Ileana Piña

 
 

Heart failure and transplantation with Dr Ileana Piña

  • ESC-HFA 2021 Can We Agree on a Universal Definition of Heart Failure?   Ileana Piña speaks with Professor Andrew Coats about the universal definition of heart failure and upcoming guidelines from the Heart Failure Association of the European Society of Cardiology.
  • ACC 2021 REHAB-HF Lays Groundwork for Recovery of Function Post HF   Ileana Pina speaks with Dalane Kitzman about a tailored strategy of physical rehabilitation to improve balance, strength, mobility, and endurance after acute HF.
  • ACC 2021 Sacubitril/Valsartan: Trending Toward PARADISE Post MI?   PARADISE-MI fell short on statistical significance but investigator Marc Pfeffer is persuaded by trends for clinical benefit. The key: 'Start the drug early and sustain it,' he tells Ileana Pina.
  • What to Know About New Hypertension Guidelines in CKD   Dr Ileana Piña asks Dr Peter A. McCullough what physicians need to know about heart failure and kidney disease, and the new hypertension guidelines in chronic kidney disease.
  • HFpEF: Do We Really Know What It Is?   Ileana Piña discusses phenotypes of patients with heart failure with preserved ejection fraction in the context of recent data from PARAGON-HF.
  • When the Patient Is the Best Practice Alert: EPIC-HF   Helping patients be proactive before their cardiology appointments can facilitate better management of HFrEF, says Larry Allen, lead author of EPIC-HF.
  • Hispanics and CVD: Country of Origin Matters   Hispanic, Latino -- the lingo and migratory patterns have changed over time, which is why clinicians should not assume that all patients share the same risk profiles, cautions Ileana Piña, MD.
  • SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context   Dr Ileana Piña asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.
  • Cookbook Medicine Won't Cut It With New Drugs for HFrEF   The plethora of new drugs means one size will not fit all patients with HFrEF. Clinicians will have to tailor their strategies, says Ileana Pina, MD.
  • Clinical Trials and the COVID-19 Conundrum   The pandemic has critically altered current clinical research. Dr Ileana Pina implores researchers to work together and 'not stop all the good work that is being done.'
  • VICTORIA PIs See Vericiguat as 'A Win' for High-Risk HFrEF   Ileana Piña gets the details on vericiguat, an investigational guanylate cyclase stimulator that may open up a new treatment pathway for high-risk heart failure.
  • Is Hyperkalemia Always Bad in Patients With HF?   Dr Ileana Piña discusses facilitating RAAS inhibitors with potassium binders for patients with renal dysfunction.
  • Do More HF Drugs Make It the Best or the Worst of Times?   New HF treatment regimens keep piling new drugs onto the old ones, making it less likely that patients will be able to adhere to the regimen, says Dr Ileana Piña.
  • Controversies in Cardiogenic Shock   Dr Ileana Piña discusses controversies surrounding cardiogenic shock, including data presented at the AHA Scientific Sessions 2019.
  • Making Room for New Drugs for Heart Failure   Drs Ileana Piña and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.
  • PROVE-HF Cracks the 'Holy Grail' of Cardiac Remodeling in HFrEF   Ileana Piña, MD speaks with lead author Jim Januzzi, MD, about the path to PROVE-HF and how sacubitril/valsartan benefits real-world patients with heart failure with reduced ejection fraction.
  • PARAGON-HF: Is There a Role for the ARNI in HFpEF?   Ileana Piña quizzes investigator Burkert Pieske on the findings for sacubitril/valsartan in patients with HFpEF, including exploratory subgroup analyses and use of mineralocorticoid-receptor antagonists.
  • Do We Need to Rethink Acute Heart Failure?   Patients with acute heart failure may comprise more than one single group, says Dr Piña.
  • 'Think Twice' Before Stopping Heart Failure Meds   Positive effects can be lost and patient outcomes adversely affected if heart failure drugs are stopped. Dr Pina reviews new evidence.
  • Hopeful Heart: Hope for Improving QoL in Depressed HF Patients   'Depression kills,' says Bruce Rollman, MD, the lead author of the Hopeful Heart study. Screening can identify HF patients at risk for depression and improve outcomes.